Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2002 3
2003 1
2004 3
2005 5
2006 5
2007 5
2008 10
2009 3
2010 11
2011 5
2012 8
2013 6
2014 7
2015 4
2016 8
2017 7
2018 2
2019 2
2020 5
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 18421139

95 results

Results by year

Filters applied: . Clear all
Page 1
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034.
Madison V, Prongay AJ, Guo Z, Yao N, Pichardo J, Fischmann T, Strickland C, Myers J Jr, Weber PC, Beyer BM, Ingram R, Hong Z, Prosise WW, Ramanathan L, Taremi SS, Yarosh-Tomaine T, Zhang R, Senior M, Yang RS, Malcolm B, Arasappan A, Bennett F, Bogen SL, Chen K, Jao E, Liu YT, Lovey RG, Saksena AK, Venkatraman S, Girijavallabhan V, Njoroge FG. Madison V, et al. J Synchrotron Radiat. 2008 May;15(Pt 3):204-7. doi: 10.1107/S0909049507064229. Epub 2008 Apr 18. J Synchrotron Radiat. 2008. PMID: 18421139 Free PMC article.
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
Prongay AJ, Guo Z, Yao N, Pichardo J, Fischmann T, Strickland C, Myers J Jr, Weber PC, Beyer BM, Ingram R, Hong Z, Prosise WW, Ramanathan L, Taremi SS, Yarosh-Tomaine T, Zhang R, Senior M, Yang RS, Malcolm B, Arasappan A, Bennett F, Bogen SL, Chen K, Jao E, Liu YT, Lovey RG, Saksena AK, Venkatraman S, Girijavallabhan V, Njoroge FG, Madison V. Prongay AJ, et al. J Med Chem. 2007 May 17;50(10):2310-8. doi: 10.1021/jm060173k. Epub 2007 Apr 20. J Med Chem. 2007. PMID: 17444623
Potent triazolyl-proline-based inhibitors of HCV NS3 protease.
Naud J, Lemke C, Goudreau N, Beaulieu E, White PD, Llinàs-Brunet M, Forgione P. Naud J, et al. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3400-4. doi: 10.1016/j.bmcl.2008.04.012. Epub 2008 Apr 10. Bioorg Med Chem Lett. 2008. PMID: 18448339
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
Wang AX, Chen J, Zhao Q, Sun LQ, Friborg J, Yu F, Hernandez D, Good AC, Klei HE, Rajamani R, Mosure K, Knipe JO, Li D, Zhu J, Levesque PC, McPhee F, Meanwell NA, Scola PM. Wang AX, et al. Bioorg Med Chem Lett. 2017 Feb 1;27(3):590-596. doi: 10.1016/j.bmcl.2016.12.013. Epub 2016 Dec 9. Bioorg Med Chem Lett. 2017. PMID: 28011221
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
Li X, Zhang YK, Liu Y, Zhang S, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Liu L, Bu W, Kazmierski WM, Wright LL, Smith GK, Jarvest RL, Duan M, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J. Li X, et al. Bioorg Med Chem Lett. 2010 Dec 15;20(24):7493-7. doi: 10.1016/j.bmcl.2010.10.007. Epub 2010 Oct 30. Bioorg Med Chem Lett. 2010. PMID: 21041080
95 results